EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults

Seth Lederman, Bruce L Daugherty, Nancy Herje, Gregory M Sullivan

Journal of Clinical Immunology · 2026

DOI: 10.1007/s10875-026-02028-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Immunology, 2026. Verfasst von Seth Lederman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tonix Pharmaceuticals, Inc, Berkeley Heights, NJ, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, CD40 Ligand, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tonix Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Blocking CD154 (CD40L) has the potential to prolong transplanted solid organ graft survival and treat autoimmune diseases. However, first-generation anti-CD154 IgG1 monoclonal antibodies (mAbs) were associated with an increased risk of thrombosis linked to Fc binding to FcγRIIa (CD32A). Here, we describe a first-in-human, phase 1 clinical trial of TNX-1500, a novel Fc-modified IgG4 anti-CD154 mAb designed to decrease binding to FcγRIIa. Healthy volunteers (N = 26) were enrolled into single-ascending dose (3, 10, and 30 mg/kg) cohorts and received TNX-1500 intravenously. TNX-1500 was generally well tolerated. Among participants receiving TNX-1500 3, 10, and 30 mg/kg, 1 (25%), 3 (38%), and 3 (38%) participants, respectively, reported ≥ 1 treatment-emergent adverse event; all were mild or moderate in severity, and none resulted in study discontinuation. There were no thromboembolic events. Pharmacokinetic analyses of TNX-1500 demonstrated a mean half-life of 37.8 and 33.8 days for 10 and 30 mg/kg, respectively, supportive of monthly dosing; dose-proportional exposure was suggested over the 3 to 30 mg/kg range. TNX-1500 blocked the primary T cell-dependent antibody response to keyhole limpet hemocyanin (KLH) at all doses and blocked the secondary response at the 10 and 30 mg/kg doses. At 3 mg/kg, TNX-1500 reduced peak secondary response to KLH by ~ 70% relative to placebo. TNX-1500 administration was associated with immediate and sustained reduction in soluble CD154. Overall, TNX-1500 demonstrated a safety profile and pharmacologic properties that support further development as an agent with potential for prevention of organ transplant rejection and treatment for autoimmune conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCD40 LigandImmunoglobulin Fc FragmentsHumansAdultMaleFemaleMiddle AgedDouble-Blind MethodYoung AdultHealthy VolunteersImmunoglobulin GHemocyaninsAdolescent

Stichwörter der Autor:innen

Allograft transplantAnti-CD154Anti-CD40LCinical trialsImmunosuppressionMonoclonal antibodies

Substanzen

Antibodies, MonoclonalCD40 LigandImmunoglobulin Fc Fragmentskeyhole-limpet hemocyaninImmunoglobulin GHemocyanins

Autor:innen und Institutionen

  • Tonix Pharmaceuticals, Inc, Berkeley Heights, NJ, USA.
  • Tonix Pharmaceuticals, Inc, Berkeley Heights, NJ, USA. greg.sullivan@tonixpharma.com.

Förderung

  • Tonix Pharmaceuticals, Inc.

Zitieren

APA

Lederman, S., Daugherty, B. L., Herje, N., & Sullivan, G. M. (2026). First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults. Journal of Clinical Immunology. https://doi.org/10.1007/s10875-026-02028-8

Vancouver

Lederman S, Daugherty BL, Herje N, Sullivan GM. First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults. Journal of Clinical Immunology. 2026. doi:10.1007/s10875-026-02028-8

BibTeX
@article{Lederman2026,
  author = {Lederman, Seth and Daugherty, Bruce L and Herje, Nancy and Sullivan, Gregory M},
  title = {First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy Adults},
  journal = {Journal of Clinical Immunology},
  year = {2026},
  doi = {10.1007/s10875-026-02028-8}
}
Kostenlos starten →